trending Market Intelligence /marketintelligence/en/news-insights/trending/2qiDH563ZHDCn7dJxBSKNg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Minerva Neurosciences appoints chief medical officer

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Minerva Neurosciences appoints chief medical officer

Minerva Neurosciences Inc. appointed Michael Davidson chief medical officer, to lead strategic development and clinical advancement of the company's products for schizophrenia, insomnia, major depressive disorder and Parkinson's disease.

Davidson is professor of psychiatry at the Sackler School of Medicine, Tel Aviv University, and has worked as a consultant for Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Roche Holding Ltd., Novartis AG, Eli Lilly & Co., BioLineRx Ltd. and Takeda Pharmaceutical Co. Ltd., among others.